1. ALLA AKTIER
  2. NYHETER
  3. ONCOPEPTIDES

Oncopeptides

Nyheter Oncopeptides Nyheter alla bolag

Oncopeptides presents new data at the European Haematology Association meeting

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that final efficacy and safety data from the ANCHOR study has been accepted as a poster presentation at the European Hematology Association meeting (EHA) in Frankfurt, Germany on June 9, 2023.

An abstract including key data is available on the following link: EHA Open Access Library.

ANCHOR is a phase 1/2 open label multicenter study evaluating the safety and efficacy of melflufen plus dexamethasone in combination with either daratumumab or bortezomib in patients with relapsed refractory multiple myeloma (RRMM). The study started in April 2018 and was prematurely closed in February 2022 with 56 patients enrolled. The final analysis continues to support the previously reported efficacy and safety data that subsequently led to the initiation of the confirmatory phase 3 LIGHTHOUSE trial. Data from the LIGHTHOUSE study was recently presented at the European Myeloma Network meeting.

“The triplet combination of melflufen plus dexamethasone and daratumumab or bortezomib, showed encouraging clinical activity in patients with RRMM who previously have received 1-4 prior lines of therapy,” says Enrique M. Ocio, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain. “The triplet combinations with melflufen showed a predictable and manageable safety profile, which are important factors for patients in later lines of therapies.”

Scientific abstract First author Abstract code 
ANCHOR (op-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma—final efficacy and safety results.Prof. Enrique M. Ocio, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain.P876

For more information, please contact:
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28

About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com. 

Attachments
Oncopeptides presents new data at the European Haematology Association meeting

Datum 2023-05-11, kl 17:00
Källa MFN
Bifogade filer
Oncopeptides presents new data at the European Haematology Association meeting
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!